iSpecimen Inc (ISPC) - Total Liabilities
Based on the latest financial reports, iSpecimen Inc (ISPC) has total liabilities worth $6.44 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ISPC operating cash flow to assess how effectively this company generates cash.
iSpecimen Inc - Total Liabilities Trend (2018–2025)
This chart illustrates how iSpecimen Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of iSpecimen Inc to evaluate the company's liquid asset resilience ratio.
iSpecimen Inc Competitors by Total Liabilities
The table below lists competitors of iSpecimen Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Marston’s PLC
LSE:MARS
|
UK | GBX1.53 Billion |
|
Shuttle Pharmaceuticals Inc
NASDAQ:SHPH
|
USA | $8.22 Million |
|
Property Franchise Group PLC
LSE:TPFG
|
UK | GBX51.32 Million |
|
KD Corporation
KQ:044180
|
Korea | ₩277.57 Billion |
|
Octopus Renewables Infra Trust
LSE:ORIT
|
UK | GBX1.50 Million |
|
Voxtur Analytics Corp
V:VXTR
|
Canada | CA$77.62 Million |
|
Tiphone Mobile Indonesia Tbk
JK:TELE
|
Indonesia | Rp4.84 Trillion |
|
Avrupa Minerals Ltd
V:AVU
|
Canada | CA$475.57K |
Liability Composition Analysis (2018–2025)
This chart breaks down iSpecimen Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see iSpecimen Inc stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.12 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.68 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how iSpecimen Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for iSpecimen Inc (2018–2025)
The table below shows the annual total liabilities of iSpecimen Inc from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.44 Million | +6.69% |
| 2024-12-31 | $6.04 Million | -0.64% |
| 2023-12-31 | $6.08 Million | +41.07% |
| 2022-12-31 | $4.31 Million | -27.32% |
| 2021-12-31 | $5.93 Million | -82.30% |
| 2020-12-31 | $33.49 Million | +24.34% |
| 2019-12-31 | $26.93 Million | +19.87% |
| 2018-12-31 | $22.47 Million | -- |
About iSpecimen Inc
iSpecimen Inc. operates marketplace that provides biospecimens to life science researchers worldwide. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. Its marketplace offers human biospecim… Read more